Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date

 
• By Bridget Silverman and Brenda Sandburg

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers